A Phase 1 Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Compared to Placebo in HSV-2 Seropositive Patients

Trial Profile

A Phase 1 Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Compared to Placebo in HSV-2 Seropositive Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Herpes simplex vaccine (Primary) ; QS 21
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jun 2011 Results were presented at the BIO International Convention.
    • 27 Jul 2010 Top-line results reported in an Antigenics media release. Data also presented at the annual meeting of the International Herpes Workshop.
    • 26 Oct 2008 Added actual number of patients, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top